NATCO Pharma Limited (NSE:NATCOPHARM)

Intra-Cellular Therapies Revenue

NATCO Pharma had revenue of 13.91B INR in the quarter ending June 30, 2025, with 2.05% growth. This brings the company's revenue in the last twelve months to 44.09B, up 1.39% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.30B with 10.68% growth.

• Revenue (ttm): 44.09B
• Revenue Growth: +1.39%
• P/S Ratio: 3.61
• Revenue / Employee: 10.98M
• Employees: 4,016
• Market Cap: 159.10B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	44.30B	4.28B	10.68%
Mar 31, 2024	40.02B	12.94B	47.76%
Mar 31, 2023	27.09B	7.62B	39.17%
Mar 31, 2022	19.46B	-1.10B	-5.35%
Mar 31, 2021	20.56B	1.41B	7.37%